Evidence map›Paper›PMID 41239892›Full record

ArticleCartilage2025

Knee Bursae: A Comprehensive Review of Clinical Evaluation, Imaging Differentiation, and the Expanding Role of Biologic Therapies.

Mahmod Hasan, Yaron Berkovich, Muhammad Khatib, Yaniv Steinfeld, Ali Sleiman, Lior Ben Zvi, Amir Abu Alhija, Eyal Ginesin, Yaniv Yonai

Abstract read
In one paragraph

Article in Cartilage, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mahmod HasanDepartment of Orthopedic Surgery, Carmel Hospital, Haifa, Israel.ORCID 0009-0005-8724-129X
Yaron BerkovichDepartment of Orthopedic Surgery, Carmel Hospital, Haifa, Israel.ORCID 0009-0005-6466-6420
Muhammad KhatibClalit Health Services, Haifa, Israel.ORCID 0009-0006-4762-7136
Yaniv SteinfeldDepartment of Orthopedic Surgery, Carmel Hospital, Haifa, Israel.ORCID 0000-0001-5257-3087
Ali SleimanDepartment of Orthopedic Surgery, Carmel Hospital, Haifa, Israel.
Lior Ben ZviDepartment of Orthopedic Surgery, Carmel Hospital, Haifa, Israel.ORCID 0000-0002-6182-2812
Amir Abu AlhijaDepartment of Orthopedic Surgery, Carmel Hospital, Haifa, Israel.ORCID 0009-0006-2649-707X
Eyal GinesinDepartment of Orthopedic Surgery, Carmel Hospital, Haifa, Israel.ORCID 0000-0001-6503-9713
Yaniv YonaiDepartment of Orthopedic Surgery, Carmel Hospital, Haifa, Israel.ORCID 0000-0002-4161-6894

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BackgroundKnee bursae are potential sources of anterior, medial, lateral, and posterior knee pain, yet many remain under-recognized in clinical practice. Emerging biological therapies offer promising, minimally invasive options for resistant bursitis, but high-level evidence is limited for several bursal types.PurposeTo systematically review the anatomy, clinical presentation, imaging characteristics, treatment strategies, and outcomes of 11 distinct knee bursae, with emphasis on the role of biologic therapies.MethodsThis systematic review followed PRISMA guidelines. PubMed and Embase were searched (2000-2024) for studies addressing anatomy, diagnosis, imaging, treatment (conservative, injection-based, biologic, or surgical), and outcomes of knee bursae. Studies involving human subjects, published in English, and reporting clinical, imaging, or therapeutic data were included. Levels of Evidence (LOE) were assigned using Oxford criteria.ResultsA total of 76 studies were included. Several randomized controlled trials (LOE I) focused on pes anserine and OA-related bursitis, while additional Level II studies assessed PRP and corticosteroids. Data on rare bursae (e.g., LCL, deep infrapatellar) were primarily derived from imaging reviews and case series (LOE III-IV). Corticosteroid injections showed recurrence rates of 20% to 40%. PRP and PRP+HA demonstrated improved pain relief and reduced recurrence in selected bursae, although protocols remain heterogeneous.ConclusionConservative management remains first-line for most bursae. PRP-based therapies, especially in pes anserine and OA-related bursitis, offer promising alternatives in refractory cases. Although several Level I-II studies support their efficacy, additional high-quality RCTs are warranted-particularly for understudied bursae.

Indexed as

bursitisknee bursaperiarticular knee structures

Identifiers

PMID41239892
PMCPMC12619696

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.